If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
Here you can find information on the design of NOVELTY and its sub-studies.
NOVELTY is a global, prospective, observational study, which is following ~12,000 patients over 3 years, with selected study sites participating in a 2-year extension study.
Watch our short animation to learn more about the NOVELTY study, who is eligible to take part and what we hope to achieve.
Download a PDF of the NOVELTY study infographic
*A phenotype is an observable characteristic or trait of a disease, such as morphology, development, biochemical or physiological properties, without necessarily any implication of a mechanism.
†An endotype is a subtype of a condition, defined by a distinct functional or pathobiological mechanism.
A sub-study examining respiratory tract biomarkers by nasal sampling has been completed in 277 patients from the Netherlands and Sweden. Protein biomarkers and gene expression data from the samples will be interpreted alongside other NOVELTY biosamples, in addition to demographic and clinical characteristics. For further information, please contact: AZNoveltyProject@astrazeneca.com
The ADPro sub-study is being conducted in the UK and is examining small airways in patients with physician-assigned asthma and/or COPD from NOVELTY. The sub-study aims to precisely characterise patients with asthma and/or COPD using imaging, physiological and metabolic measures to assess small airways dysfunction. These techniques will enable investigators to describe the rate and pattern of disease progression in patients with different clinical features. For further information, please contact: AZNoveltyProject@astrazeneca.com
You are now leaving: http://aznoveltyproject.com/
By following this link you will be leaving the NOVELTY study website.
Please note that AstraZeneca does not take responsibility for the content displayed on other websites.